AMES, IA, January 24, 2008 — BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced that Kerry Frey, formerly President and Chief Operating Officer, will now be President and Chief Executive Officer. Eric Henderson, who was Chief Executive Officer, will now be Executive Vice President and Chief Science Officer, a newly created position.
Henderson, age 51, said, “I am very happy and excited about this change in our duties. I am a scientist by training and look forward to spending more time doing what I love – research. I intend to lead our efforts to develop new products to support our flagship device, the Nano eNabler™ molecular printer. The company is now at a stage where a genuine businessman needs to step into the CEO’s job, and I have every confidence that Kerry is the right person for BioForce at this point in its development.
Frey, age 62, said, “BioForce has made the transition from a development-stage entity to a commercial enterprise, and we needed to structure our management team to reflect that progression and to ensure continued growth of our company. I have the background, training and experience to guide BioForce to where its shareholders want it to be.
“BioForce has made great strides in the last year or so culminating in a fourth quarter 2007 in which we sold 5 Nano eNablers, four of them through our overseas distributors. That brings the year’s total to 9, and to 11 since inception. With customers on three continents, a US sales force actively pursuing business, and an expanding international distribution network, we are poised for a strong 2008.”
Frey concluded, “In taking on these responsibilities, I can and will rely on our CFO, Greg Brown who has broad experience managing both startup companies and venture capital firms. Eric will, of course, continue to participate in the management of BioForce, but by freeing his scientific talents, we have actually leveraged his abilities to ensure that BioForce continues to develop innovative commercial products and research, remaining on the cutting edge of nano-biotechnology.”